Free Trial

Xenon Pharmaceuticals (XENE) Insider Trading & Ownership

Xenon Pharmaceuticals logo
$38.63 -0.27 (-0.69%)
(As of 12/20/2024 05:31 PM ET)

Xenon Pharmaceuticals (NASDAQ:XENE) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
5.52%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
4
Amount Of
Insider Selling
(Last 12 Months)
$1.90 M
Get XENE Insider Trade Alerts

Want to know when executives and insiders are buying or selling Xenon Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

XENE Insider Buying and Selling by Quarter

Xenon Pharmaceuticals Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/18/2024Sherry AulinCFOSell18,709$41.21$770,997.89  
11/22/2024Gary PatouDirectorSell4,891$41.08$200,922.28  
3/7/2024Sherrington RobinEVPSell7,137$46.28$330,300.36  
3/7/2024Steven GannonDirectorSell13,000$46.28$601,640.00  
(Data available from 1/1/2013 forward)

XENE Insider Trading Activity - Frequently Asked Questions

5.52% of Xenon Pharmaceuticals stock is owned by insiders. Learn more on XENE's insider holdings.

The following insiders have sold XENE shares in the last 24 months: Christopher John Kenney ($24,507.00), Dawn Svoronos ($967,500.00), Gary Patou ($648,042.48), Ian Mortimer ($1,310,833.55), Sherrington Robin ($330,300.36), Sherry Aulin ($770,997.89), Simon N Pimstone ($3,130,955.56), and Steven Gannon ($601,640.00).

Insiders have sold a total of 194,230 Xenon Pharmaceuticals shares in the last 24 months for a total of $7,784,776.84 sold.

Xenon Pharmaceuticals Key Executives

  • Mr. Ian C. Mortimer C.M.A. (Age 48)
    CPA, M.B.A., President, CEO & Director
    Compensation: $1.07M
  • Ms. Sherry Aulin C.A. (Age 41)
    CPA, Chief Financial Officer
    Compensation: $664.8k
    1 recent trades
  • Dr. Robin P. Sherrington Ph.D. (Age 63)
    Executive Vice President of Strategy & Innovation
    Compensation: $587.03k
  • Dr. Christopher E. Von Seggern M.B.A. (Age 45)
    M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer
    Compensation: $621.12k
  • Dr. Christopher John Kenney M.D.Dr. Christopher John Kenney M.D. (Age 53)
    Chief Medical Officer
    Compensation: $719.82k
  • Ms. Andrea DiFabio J.D. (Age 56)
    Chief Legal Officer & Corporate Secretary
    Compensation: $200.51k
  • Ms. Shelley McCloskey B.A. (Age 64)
    Executive Vice President of Human Resources
  • Dr. James R. Empfield Ph.D. (Age 63)
    Executive Vice President of Drug Discovery
    Compensation: $323.43k
  • Ms. Sheila M. Grant M.B.A.
    M.Sc., MBA, Executive Vice President of R&D Operations


This page (NASDAQ:XENE) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners